Gabelli Funds LLC Sells 885 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Gabelli Funds LLC reduced its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.4% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 25,035 shares of the medical research company’s stock after selling 885 shares during the quarter. Gabelli Funds LLC’s holdings in Thermo Fisher Scientific were worth $13,024,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Jump Financial LLC increased its stake in Thermo Fisher Scientific by 1,545.2% in the fourth quarter. Jump Financial LLC now owns 49,011 shares of the medical research company’s stock valued at $25,497,000 after acquiring an additional 46,032 shares during the last quarter. Anchor Investment Management LLC raised its holdings in shares of Thermo Fisher Scientific by 0.9% during the 4th quarter. Anchor Investment Management LLC now owns 11,465 shares of the medical research company’s stock valued at $5,965,000 after buying an additional 99 shares in the last quarter. Kane Investment Management Inc. bought a new stake in Thermo Fisher Scientific in the 4th quarter worth approximately $747,000. Guggenheim Capital LLC grew its position in Thermo Fisher Scientific by 6.1% during the fourth quarter. Guggenheim Capital LLC now owns 40,621 shares of the medical research company’s stock valued at $21,132,000 after acquiring an additional 2,328 shares during the last quarter. Finally, Rossby Financial LCC purchased a new position in shares of Thermo Fisher Scientific during the fourth quarter worth approximately $920,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Down 0.9 %

NYSE:TMO opened at $436.90 on Thursday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. The firm’s 50-day moving average price is $502.59 and its 200-day moving average price is $536.26. The company has a market capitalization of $164.93 billion, a PE ratio of 26.43, a P/E/G ratio of 2.99 and a beta of 0.86. Thermo Fisher Scientific Inc. has a 1-year low of $409.85 and a 1-year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. On average, equities analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, April 15th. Investors of record on Friday, March 14th were paid a $0.43 dividend. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. The ex-dividend date was Friday, March 14th. This represents a $1.72 dividend on an annualized basis and a yield of 0.39%. Thermo Fisher Scientific’s payout ratio is presently 10.41%.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the stock. Royal Bank of Canada set a $693.00 target price on shares of Thermo Fisher Scientific in a research report on Friday, January 31st. Barclays lowered their target price on Thermo Fisher Scientific from $620.00 to $475.00 and set an “equal weight” rating for the company in a research note on Thursday, April 10th. Raymond James restated an “outperform” rating and set a $667.00 price target (up from $650.00) on shares of Thermo Fisher Scientific in a research report on Monday, February 3rd. StockNews.com raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Tuesday, January 14th. Finally, Sanford C. Bernstein upgraded shares of Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 price target for the company in a report on Friday, January 10th. Four equities research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $647.43.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $516.67, for a total transaction of $5,166,700.00. Following the completion of the sale, the chief executive officer now owns 115,174 shares of the company’s stock, valued at $59,506,950.58. This trade represents a 7.99 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Michael A. Boxer sold 3,775 shares of the stock in a transaction on Monday, March 10th. The shares were sold at an average price of $532.52, for a total value of $2,010,263.00. Following the sale, the senior vice president now owns 10,816 shares in the company, valued at approximately $5,759,736.32. This represents a 25.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 23,900 shares of company stock worth $13,106,062. 0.34% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.